Cabaletta Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 9, 2026, specifically the Company's Annual Meeting of Stockholders. Cabaletta Bio, Inc. is a Delaware corporation with its principal executive offices in Philadelphia, Pennsylvania.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. No financial statements are included in this document.
Material Changes and Corporate Actions
- Charter Amendment Approved: Stockholders approved an amendment to the Third Amended and Restated Certificate of Incorporation, increasing the number of authorized common shares from 300,000,000 to 600,000,000. The Certificate of Amendment was filed with the Delaware Secretary of State and became effective immediately.
- Director Elections: Stockholders elected Scott Brun, M.D., and Shawn Tomasello, MBA, as Class I directors for three-year terms expiring in 2029.
- Proposal Withdrawal: The Board of Directors withdrew Proposal 3 (Plan Amendment Proposal) from consideration prior to the vote.
- Outstanding Shares: As of the record date (April 20, 2026), there were 111,324,796 outstanding shares of voting common stock.
Voting Results and Management Commentary
The following proposals were submitted to a vote at the Annual Meeting:
- Proposal 1 (Directors): Approved. Scott Brun received 39,537,359 votes "For" and Shawn Tomasello received 28,606,240 votes "For".
- Proposal 2 (Auditor Ratification): Approved. Ernst & Young LLP was ratified with 82,076,950 votes "For".
- Proposal 4 (Charter Amendment): Approved. The increase in authorized shares received 80,398,225 votes "For".
- Proposal 5 (Executive Compensation): Approved on a non-binding advisory basis with 27,490,145 votes "For" against 26,048,082 votes "Against".
- Proposal 6 (Adjournment): Approved, though deemed not necessary as sufficient proxies were present to approve the Charter Amendment.
Investor Verification Checklist
- Verify the effective date of the Certificate of Amendment filed with the State of Delaware (Exhibit 3.1).
- Review the definitive Proxy Statement (Schedule 14A) filed on April 28, 2026, for detailed rationale behind the charter amendment and director elections.
- Confirm the impact of the increased authorized share count on future capital raising capabilities and potential dilution.
- Note the significant "Against" vote on executive compensation (Proposal 5), which may indicate stockholder sentiment regarding pay practices.